We understand the unique challenges presented ophthalmic development and formulation. We have significant development experience in all ophthalmic dosages forms:
-Depot and sustained release technology
- Proprietary (DiFFer) dynamic diffusion model has been developed and validated to model formulation diffusion and erosion characteristics. Our model closely resembles topical ophthalmic administration in-vivo in cornea and scleral tissue. Formulations can be screened and optimized prior to in-vivo studies.
Small volume vessel for early development activity of solutions and emulsions.
Pilot scale plant for production of pre-clinical and clinical supplies, process scale-up. Jacketed tank with homogenizer for production of suspensions, emulsions, and other semi-solid dosage forms.
Enables high shear particle size reduction, uniform particle size reduction, easy scale-up, improved bioavailability, allowing our team develop innovative methods for targeted drug delivery using multi-functional nano-medicine
Add a footnote if this applies to your business